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A complex dynamic ultradian rhythm underlies the hypothalamic–pituitary–adrenal (HPA) circadian rhythm. We have investigated in
normal human male subjects the importance, site of action, and receptor-mediated processes involved in rapid basal corticosteroid
feedback and its interaction with corticotrophin releasing hormone (CRH) drive. Pro-opiomelanocortin (POMC), ACTH, and cortisol
were measured every 10 min from healthy males during the awakening period or late afternoon using an automated blood sampling
system.Mathematical modeling into discrete pulses of activity revealed that intravenous infusion of the syntheticmixed glucocorticoid/
mineralocorticoid agonist prednisolone produced rapid inhibition of ACTH and cortisol pulsatility within 30 min in the morning and
afternoon.Anypulse that had commenced at the timeof injectionwasunaffected, and subsequent pulsatilitywas inhibited. Prednisolone
also inhibitedACTHand cortisol secretion in response to exogenous CRH stimulation, inferring rapid feedback inhibition at the anterior
pituitary.CirculatingPOMCpeptide concentrationswereunaffected, suggesting that the rapid corticosteroid inhibitory effect specifically
targeted ACTH secretion from pituitary corticotrophs. Prednisolone fast feedback was only reduced by glucocorticoid receptor antago-
nist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a glucocorticoid receptor-mediated pathway. The
intravenous prednisolone suppression test provides a powerful new tool to investigate HPA abnormalities underlying metabolic and
psychiatric disease states.
Introduction
The hypothalamic–pituitary–adrenal (HPA) axis is characterized
by a circadian rhythm, underpinned by a dynamic ultradian
rhythm comprising discrete pulses of ACTH and glucocorticoid
secretion (Carnes et al., 1989;Windle et al., 1998). HPA activity is
tightly controlled via complex regulatory mechanisms of glu-
cocorticoid negative feedback involving signaling networks at the
pituitary, hypothalamus, and hippocampus (Watts, 2005). The
underlying HPA control mechanism of endogenous cortisol
feedback inhibition was first discovered by Moore and Price
(1932). Although the basic tenet remains, there is new evidence
that ultradian rhythmicity itself is attributable to an oscillatory
feedforward–feedback relationship between the pituitary and ad-
renal gland (Walker et al., 2010). The feedback components of
the HPA axis are assumed to act on the two basic processes of
peptide synthesis and release (Watts, 2005), mediated via
genomic processes through glucocorticoid receptor (GR) and
mineralocorticoid receptor (MR) activation (De Kloet et al.,
1998). This simple paradigm is probably an oversimplification. It
cannot account for multiple sites of action or differential glu-
cocorticoid effects during different physiological conditions and
disease states, including depression and the metabolic syndrome
(Maddock and Pariante, 2001; Pariante and Miller, 2001). In-
deed, there is increasing evidence for nongenomic mechanisms
of negative feedback, although differentiation fromgenomic pro-
cesses remains controversial (Haller et al., 2008).
Glucocorticoids have been shown to act in rapid nongenomic
time domains (fast feedback) (Dallman and Yates, 1969). This
has been well documented in rats (Dallman and Yates, 1969;
Keller-Wood and Dallman, 1984; Atkinson et al., 2008), and,
although there is evidence suggesting a similar mechanism in
man (Fehm et al., 1979), it has not been investigated in detail.
These rapid effects are important for physiological responses to
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pulsatile glucocorticoid secretion (Stavreva et al., 2009) and may
help regulate its characteristic ultradian rhythmicity (Atkinson et
al., 2008) via feedforward–feedback loops (Jacobson, 2005;
Walker et al., 2010).
Previous studies on negative feedback in humans have pre-
dominately used the potent glucocorticoid agonist dexametha-
sone to inhibit HPA activity over long time domains and have
been used in the investigation of affective disorders or Cushing’s
disease (Schmider et al., 1995; Deuschle et al., 1998; Castro et al.,
2003; Grossmann et al., 2004). These studies do not reflect feed-
back from endogenous pulses of cortisol, which act in a faster
time domain and activate both glucocorticoid and mineralocor-
ticoid receptors.
To allow us to determine the dynamics of feedback, we used
our human automated blood sampling system (HABS) (Henley
et al., 2009) that can painlessly and accurately take frequent ve-
nous blood samples for measurement of ultradian hormone se-
cretion under basal conditions. This allowed us to capture rapid
inhibition of ACTH and cortisol secretion after intravenous ad-
ministration of prednisolone. We chose to use the synthetic cor-
ticosteroid prednisolone because it has MR and GR binding and
activating characteristics similar to cortisol (Grossmann et al.,
2004). Used together, the HABS and prednisolone suppression
test have allowed, for the first time, the study in healthy males of
the characteristics of inhibitory glucocorticoid responses within a
rapid time domain, their site and mechanism of action, and im-
portance of endogenous hypothalamic drive.
Materials andMethods
Participants
A total of 36 healthy male volunteers (aged 18–34 years, mean of 22
years) were recruited from the students and staff of the University of
Bristol (Bristol, UK). Exclusion criteria included (1) body mass index
18 or 30 kg/m2; (2) medications (including inhalers and steroid
creams) except the occasional paracetamol or aspirin in the last 2
months; (3) a history of anxiety, depression, or psychosis; (4) a history of
psychosis in a first-degree relative; and (5) allergic reaction or contrain-
dication to any of the study medications used.
This research was conducted in accordance with the Helsinki prin-
ciples: all participants gave informed written consent before their
participation in the study. The study had full ethical approval from
the Bath Research Ethics Committee and approval by the Institutional
Review Boards of the University Hospitals of Bristol and the Univer-
sity of Bristol. In addition, the study was discussed with theMedicines
and Healthcare Products Regulatory Authority and formal approval
was deemed unnecessary.
Blood sampling and processing
Participants were cannulated twice, once in each vein of the antecu-
bital fossa. One cannula was used for collection of venous blood via
our HABS described previously by Henley et al. (2009) and the other
for the administration of the study reagents. The HABS allows a ve-
nous blood sample (3 ml) to be drawn at 10 min intervals via an
automated computerized pump. Blood samples were taken for
ACTH, cortisol, pro-opiomelanocortin (POMC), and prednisolone
levels into EDTA, serum separator tube II, and lithium–heparin tubes
and separated within 30 min. Samples for ACTH and POMC were
kept on ice until separation. Plasma was divided into aliquots for the
different assays and stored at 80°C until analysis.
Assays
Cortisol levels were determined by RIA (Netria): assay sensitivity, 5
nmol/L; intra-assay coefficient of variation (CV), 5.8%; interassay CV,
9.2%; and cross reactivity with prednisolone, 6% (Cortisol RIA kit
IM1841; Immunotech). Samples were assayed in duplicate. ACTH levels
were processed via chemiluminescent immunometric assay using the
Immulite 2000 ACTH kit (Pichler et al., 2004; Raff, 2008): sensitivity, 5
pg/ml; intra-assay CV, 6.7%; and interassay CV, 8.2%. Samples were
analyzed singly. Very low ACTH values after prednisolone were docu-
mented as 5 pg/ml by the analyzer, so for deconvolution analysis, the
lower end of the ACTH curve was further calibrated using a polynomial
trend line and the equation produced used to deduce ACTH concentra-
tion from the counts per second.
Prednisolone levels (combination of two 10-min samples) were mea-
sured via HPLC by the Department of Clinical Biochemistry, Royal
Brompton Hospital (London, UK) (Robinson et al., 2003). At the pred-
nisolone concentrations being measured, the CV was 3.4%. The mini-
mum detection limit for the HPLC was 20 nmol/L.
POMC levels were performed using a two-site monoclonal antibody-
based ELISA (Rousseau et al., 2007). This had a 100% cross-reactivity for
POMCand pro-ACTHwith a lower limit of detection of 5 pmol/L and an
interassay and intra-assay CV of10%.
Drugs
Prednisolone sodium succinate (SoluDecortin H) was obtained from
Merck, and ovine corticotrophin releasing hormone (oCRH) was from
Ferring Pharmaceuticals and prepared according to the instructions of
the manufacturer. All drugs were prepared immediately before adminis-
tration. Prednisolone sodium succinate is the water-soluble form of
prednisolone, and cleavage of the ester occurs very rapidly after intrave-
nous injection; free prednisolone levels can be measured 5 min after the
injection (Rose et al., 1981; Boudinot and Jusko, 1986). For the mecha-
nistic studies, mifepristone was purchased from Exelgyn, and spirono-
lactone (nonproprietary) was from Alpharma.
Experimental protocol
In all studies, six participants attended twice in a blinded randomized
order, once for an injection of 10 mg of prednisolone sodium succinate
(equivalent to 7.5 mg of prednisolone) over 5 min and the other for an
injection of placebo (equal volume of normal saline) over 5 min. During
all testing schedules, the participant was in a separate room to the HABS.
The lines connected to the HABS and the line used to deliver the pred-
nisolone, placebo, or other intravenous study medications was passed
through a small hatch in the wall above the bed/chair of the participant.
If a participant wanted to be disconnected from the HABS to go to the
bathroom, this was done between blood samples. During the daytime,
participants were free to read, do university work, watch DVDs, etc., and
could chose to sit on either a chair or a bed.
Experiment 1: prednisolone-induced feedback inhibition in the early
morning. Participants attended the Joint Clinical Research Unit (JCRU)
(UniversityHospitals of Bristol, Bristol, UK) at 10:00 P.M. on the night of
testing and cannulated twice. A 30 min HABS acclimatization sequence
was performed before lights off at 11:00 P.M. A repeat acclimatization
sequence was performed at 4:30 A.M. to ensure that the cannula was still
functioning, and the first blood sample was drawn at 5:00 A.M. Ten
minute blood samples for the assay of ACTH, cortisol, and POMC were
taken throughout the experimental protocol, except for participant H1,
who had 10 min venous blood samples taken for the assay of pred-
nisolone levels instead of POMC to calculate the rate of rise of prednsi-
olone. Because of the volume of blood required for prednsiolone HPLC,
it was not possible to collect a simultaneous sample for the assay of
POMC. At 6:02 A.M., participants received 10 mg of prednisolone so-
dium succinate intravenously or placebo manually over 5 min. Lights
switched on at 7:00 A.M., breakfast was served at 8:00 A.M., and the last
blood sample was taken at 12:00 P.M.
Experiment 2: prednisolone-induced feedback inhibition in the after-
noon/evening. Participants attended the JCRU at 2:00 P.M. and cannu-
lated by 2:30 P.M. At 3:00 P.M., a 30minHABS acclimatization sequence
was performed. At 3:30 P.M., the first blood sample was drawn. Ten
minute venous blood samples for the assay of ACTH, cortisol, and
POMC levels were taken throughout the experimental protocol, except
for participant L1, who had 10 min venous blood samples taken for the
assay of prednisolone levels taken instead of POMC as explained in ex-
periment 1. At 4:32 P.M., participants received 10 mg of prednisolone
sodium succinate intravenously or placebomanually over 5 min. Dinner
was served at 7:30 P.M., and the last blood samplewas taken at 10:30 P.M.
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Experiment 3: level of response of prednisolone-induced feedback inhibi-
tion. Protocol for experiment 2 was repeated. In addition, participants
received two bolus intravenous injections of oCRH at a dose of 1 g/kg:
CRH(1) was given at 4:47 P.M., 10 min after placebo/prednisolone;
CRH(2) was given 3 h after CRH(1), at 7:37 P.M.
Experiment 4: GR and MR contribution to prednisolone-mediated fast
feedback. Participants were divided into three subgroups (placebo, mife-
pristone, and spironolactone), with six participants per group. Accord-
ing to the subgroup, the following combination of additional study
medications were administered: oral placebo, mifepristone at 600 mg
orally (GR antagonist), or spironolactone at 400 mg orally (MR antago-
nist). Whichever additional study medications the participants received
on their first visit, they also received on their second visit. The order of
study subgroup was randomized in a double-blind manner. Participants
attended the JCRU at 8:45 A.M. and were cannulated by 9:15 A.M. At
9:30 A.M., a 30 min HABS acclimatization sequence was performed and
participants received their study medications. At 10:00 A.M., the first
blood sample was drawn. Tenminute venous blood samples for the assay
of ACTH and cortisol levels were taken throughout the experimental
protocol. Of note, preintervention sampling was extended to 2 h. At
12:02 P.M., participants received 10 mg of prednisolone sodium succi-
nate intravenously or placebo manually over 5 min. Lunch was served at
1:00 P.M., and the last blood sample was taken at 5:00 P.M.
Statistical analyses
Data are presented as means SE. For all statistical tests, significance at
p 0.05 was used. Comparison between treatment groups was analyzed
using area under the curve (AUC) and all pairwise two-way repeated-
measures (RM) ANOVA using the Holm–Sidak method. The complete
10 min data were separated into smaller timeframes. Results presented
are for the absolute values (un-normalized) and normalized (average
preintervention activity) data.
ACTH and cortisol concentration time series were analyzed using a
recently developed automated deconvolution method, which was math-
ematically verified by direct statistical proof and empirically validated
using hypothalamic–pituitary sampling and simulated pulsatile time se-
ries (Keenan et al., 2001, 2003). The MATLAB-based algorithm first
detrends the data andnormalizes concentrations to the unit interval [0,1]
(Keenan et al., 2005). Second, the program creates multiple successive
potential pulse-time sets, each containing one fewer burst via a smooth-
ing process (a nonlinear adaption of the heat-diffusion equation). Third,
a maximum-likelihood expectation estimation method computes all se-
cretion and elimination parameters simultaneously conditional on each
of the candidate pulse-time sets.Deconvolutionparameters comprisebasal
secretion (0), twohalf-lives (1,2), secretory-burstmass (0,1), random
effects on burst mass (A), measurement error (), and a three-parameter
flexible gamma secretory-burst waveform (1, 2, 3). For ACTH, the fast
half-lifewas representedas 3.5min, constituting37%of thedecay amplitude
(Iranmanesh et al., 1993). The slowhalf-life was represented as an unknown
variable between 14 and 35min. For cortisol, the rapid half-life was fixed at
2.4 min (37% of decay amplitude), and the slow half-life was estimated as a
variable (56min)within the expected rangeof 40–85min (Bright, 1995).All
candidate pulse-time sets were deconvolved. Statistical model selection was
then performed to distinguish among the independently framed fits of the
multiple candidate pulse-time sets using the Akaike information criterion
(Akaike, 1974). Observed interpulse intervals were described by a two-
parameterWeibull process (more general form of a Poisson process, which
uncouples the mean from the variance). The parameters (and units) are
frequency (number of bursts per total sampling period,  ofWeibull distri-
bution), regularity of interpulse intervals (unitless  of Weibull), slow half-
life (minutes), basal and pulsatile secretion rates (concentration units/
session),mass secretedper burst (concentrationunits), andwaveformshape
[mode or time delay to maximal secretion after objectively estimated burst
onset (minutes)]. To calculate average pulse mass according to the time-
frame of the first 2 h (0–120min) and the last 3 h (121–360min) postinter-
ventionstart time,pulsatile activity includedwasbasedonpredictedputative
pulse onset occurring within the allotted timeframe. Results presented are
for the absolute values and normalized (average placebo pulse mass used as
surrogate marker for baseline activity for experiments 1–3, baseline prein-
tervention activity for experiment 4) data. For the afternoon studies decon-
volution analysis data, subject L1was excluded as a result of a stress response
onhis first visit (placebo interventionday). Stress response exclusion criteria
included a double than or greater difference in preintervention pulse mass
between placebo and prednsiolone subgroups. Comparisonswithin and be-
tween treatment groups were analyzed using a two-tailed paired Student’s t
test. If therewasnodetectable activity after intervention, theminimaldetect-
able pulsemass for the programwas assigned (1 pg/ml ACTHand 3 nmol/L
cortisol).
For the participants who received the prednisolone intervention dur-
ing an interpulse interval, time to inhibition was calculated as the time
taken from the start of prednisolone intervention to the next putative
pulse onset as estimated by deconvolution analysis. Evidence of partial
inhibition was taken as 50% of baseline activity and complete inhibi-
tion as30% of baseline activity.
To quantitate the orderliness or regularity of consecutive serum
POMC levels over the sampling period, approximate entropy (ApEn)
was used. Normalized ApEn parameters of m 1 (run length) and r
20% (tolerance window) of each series SDwere used. The distribution of
empirically “random” (maximal) ApEn values were determined by 1000
random shuffles of ordered sample values within each time series. There-
fore, the ApEn of each “observed” (unshuffled) time series was also eval-
uated as a mean ratio of observed-to-random ApEn (Veldhuis et al.,
2001). Higher absolute ApEn values denote greater relative randomness
of hormone secretion pattern (Pincus and Keefe, 1992).
Results
Experiment 1: prednisolone inhibition of ACTH and cortisol
secretion during the morning
Ten minute sampling (Fig. 1) of acute administration of pred-
nisolone produced a significant decline inACTHvalueswithin 60
Figure 1. Six healthymale subjects sampled at 10min intervals for ACTH (A) and cortisol (B)
presented as group means SEM. Subjects attended twice and were given either an intrave-
nous injection of 10 mg of prednisolone sodium succinate (black squares) or placebo (gray
squares) over 5 min at 6:02 A.M. (shaded vertical line) (period of lights off indicated by
shaded horizontal line). Prednisolone (gray circle dotted line) had a rate of rise of 21
nmol  L1  min1 in the first 20 min. A steady-state concentration was then reached, and
levels began to decline 40 min later. * denotes first significant difference between the pred-
nisolone and placebo groups.
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min ( p  0.001, RM-ANOVA) and for cortisol within 70 min
( p 0.001, RM-ANOVA) on both absolute values and normal-
ized data. There was no significant difference in preintervention
ACTH and cortisol values.
ACTH and cortisol pulsatility were significantly reduced after
prednisolone ( p 0.01) (supplemental Table 1A,B, available at
www.jneurosci.org as supplemental material), and there was a
significant reduction in ACTH basal secretion ACTH ( p 0.05)
(supplemental Table 1A, available at www.jneurosci.org as sup-
plemental material). Overall cortisol basal secretion was also re-
duced but was not significantly apparent after deconvolution
(supplemental Table 1B, available at www.jneurosci.org as sup-
plemental material). After prednisolone, there was a significant
reduction in average ACTH and cortisol pulse mass within 2 h in
the prednisolone group compared with baseline activity (ACTH,
p 0.001 absolute values/normalized; cortisol, p 0.01 absolute
values/normalized) and placebo at a similar timeframe ( p 0.05
absolute values, p  0.001 normalized; and p  0.01 absolute
values, p 0.05 normalized, respectively). The degree of inhibi-
tion continued until the end of the sampling period (supplemen-
tal Tables 2A–C, 3A–C, available at www.jneurosci.org as
supplemental material). In the placebo group, there was a signif-
icant increase in average pulse mass for ACTH corresponding
with the awakening period ( p 0.01 absolute values; p 0.001
normalized). From2hafterplacebo interventionuntil the endof the
sampling period, the average ACTH pulse mass was significantly
smaller than baseline activity ( p 0.05 absolute values; p 0.001
normalized) but still greater than the corresponding prednisolone
group ( p 0.005 absolute values; p 0.005 normalized).
For cortisol, in the placebo intervention group, the average
pulsemass in the first 2 h after placebo intervention (correspond-
ing with the awakening rise) was significantly larger than the
remainder of the sampling period ( p 0.05 absolute values; p
0.005 normalized). There was no difference from baseline for
cortisol for either the average pulse mass in the first 2 h after
intervention or the remainder of the sampling period.
Experiment 2: prednisolone inhibition on ACTH and cortisol
secretion during the late afternoon
Acute administration of prednisolone to normal volunteers in
the late afternoon (Fig. 2) produced a significant decline within
10min for ACTH ( p 0.005 absolute values; p 0.001 normal-
ized, RM-ANOVA) and also for cortisol levels (absolute values
nonsignificant, p 0.001 normalized, RM-ANOVA). There was
no difference in preintervention sampling.
There was a significant reduction in ACTH total pulsatility
and basal secretion after prednisolone ( p  0.05), although no
such difference was detectable for cortisol (supplemental Table
1A,B, available at www.jneurosci.org as supplemental material).
After prednisolone, there was a significant reduction in ACTH
and cortisol pulse mass compared with the placebo intervention
(ACTH, p 0.05 absolute values, p 0.001 normalized; cortisol
normalized data, p 0.05) and baseline activity (ACTH, p 0.01
absolute values, p  0.001 normalized; and cortisol, p  0.05
absolute values, p 0.001 normalized) within 2 h (supplemental
Tables 4, 5, available at www.jneurosci.org as supplemental ma-
terial). This degree of inhibition continued until the end of the
sampling period for ACTH only. For cortisol, two of the subjects
regained their endogenous pulsatility; consequently, there was no
Figure 2. Six healthymale subjects sampled at 10min intervals for ACTH (A) and cortisol (B)
presented as group means SEM. Subjects attended twice and were given either an intrave-
nous injection of 10 mg of prednisolone sodium succinate (black triangles) or placebo (gray
triangles) over 5 min at 4:32 P.M. (shaded vertical line). Prednisolone (gray circle dotted line)
achieved a rate of rise of 20 nmol  L1  min1 in the first 20 min. A steady-state concentra-
tion was then reached, and levels began to decline 40 min later. * denotes first significant
difference between the prednisolone and placebo groups.
Figure 3. Comparison of morning (squares) and afternoon (triangles) studies. Six healthy
male subjects sampled at 10 min intervals for ACTH (A) and cortisol (B) presented as group
normalized means  SEM. Subjects attended twice and were given either an intravenous
injectionof 10mgofprednisolone sodiumsuccinate (black) or placebo (gray) over 5min, 62min
into sampling (vertical line).
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statistically significant difference in average
pulse mass between the placebo and pred-
nisolone intervention groups after 2 h.
The placebo group, as expected at this
time of day, showed a general decline in
ACTH ( p  0.05 absolute values; p 
0.005 normalized) and cortisol ( p 0.05
normalized) levels over the sampling pe-
riod compared with baseline sampling.
Direct comparison of morning and
afternoon responses to corticosteroid
On examination of the normalized ACTH
and cortisol data, there were no differ-
ences in the responses elicited by pred-
nisolone at the two times of day as shown
through assessment of AUC, RM-ANOVA,
and average pulse mass according to time-
frame (Fig. 3). In the placebo intervention
groups, the morning studies produced a
greater normalized AUC for ACTH ( p 
0.05) and cortisol ( p 0.001). Normalized
average pulse mass confirmed a greater
ACTHpulsemass in the first 2 h after inter-
vention, corresponding to the awakening
response. This did not reach statistical sig-
nificance for cortisol. Basal ACTH and cor-
tisol secretion in the placebo intervention
groups was similar at both times of day, as
was the reduced ACTH basal secretion seen
after prednisolone.
Interaction of glucocorticoid inhibition
on ACTH and cortisol with phase of
endogenous ultradian rhythm
Hormone pulses that were initiated at the
time of prednisolone injection continued in
a classical manner (Fig. 4A,B). Subsequent
pulsatile activity was either inhibited (typically30% bymass) and
appeared delayed or was absent. Subjects may or may not have ex-
hibitedrecoveryof endogenouspulsatilityby theendof the sampling
period. Consequently, it was difficult to interpret when pulsatility
was first affected.
If, however, the injection of prednisolone was given during
the interpulse period (Fig. 4C), the subsequent pulse occurred at
a time that appeared appropriate but was smaller than expected,
and the degree of inhibition was related to the length of time after
prednisolone and the putative pulse onset time; the greater the
time from prednisolone treatment to pulse onset, the greater the
degree of inhibition. Partial inhibition (50% by mass) was first
documented at 8min after prednisolone and complete inhibition
by 10–12 min after prednisolone for both morning and after-
noon studies. Pearson’s product moment correlation (Fig. 5)
confirmed a negative correlation between time to inhibition and
pulse mass expressed as a percentage of baseline for ACTH (r
0.9, p  0.01, n  6). A similar negative correlation existed for
cortisol but did not reach significance (r0.7, p value was non-
significant, n 5).
Experiment 3: prednisolone inhibition of ACTH and cortisol
secretion after oCRH stimulation
Prednisolone in combination with oCRH produced a significant
decline inACTHvalueswithin 50min ( p 0.001, RM-ANOVA)
for both absolute and normalized values compared with placebo
and oCRH. For cortisol, the inhibition occurred within 10 min
for the absolute values ( p  0.001) and within 70 min for nor-
malized cortisol ( p 0.001) (Fig. 6). There was no difference in
preintervention sampling.
For both ACTH and cortisol, acute intravenous injection of
prednisolone inhibited the response to both CRH(1) ( p  0.05
and p  0.05) and CRH(2) ( p  0.01 and p  0.05) injections
Figure 4. Examples of participants’ ACTH profiles and corresponding mathematically modeled pulsatile activity after placebo
(gray) and prednisolone (black) in the morning (squares) and afternoon (triangles) are shown. In A, the participant received
prednisolone at the beginning of a pulse of activity, in B at the end of an endogenous pulse, and C during an interpulse interval.
Estimated putative pulse onsets are documented by black triangles above the time line of the mathematically modeled profiles.
Figure 5. Relationship between time to inhibition (minutes) after prednisolone and
degree of inhibition (expressed as percentage of baseline average pulse mass) for ACTH
pulsatility (r0.9, p 0.01, n 6).
6110 • J. Neurosci., April 28, 2010 • 30(17):6106–6115 Russell et al. • GR-Mediated Rapid HPA Inhibition in Humans
more than placebo intervention. Prednisolone reduced the re-
sponse to CRH(2) more than CRH(1) for both ACTH and corti-
sol ( p 0.05). After placebo, the response toCRH(2)was smaller
than CRH(1) for ACTH only ( p  0.05) (supplemental Table
6B–D, available at www.jneurosci.org as supplemental material).
Total pulsatility was significantly reduced in the prednisolone
intervention arm for ACTH and cortisol ( p 0.01 and p 0.05
respectively) (supplemental Table 6A, available at www.
jneurosci.org as supplemental material).
On examination of putative pulse onset times, the injection of
oCRH synchronized the subjects by inducing a pulse of activity.
There was evidence of inhibition of ACTH pulsatile activity in all
subjects within 20 min and for cortisol within 30 min for all but
one subject.
ACTH basal secretion was reduced after prednisolone ( p 
0.01) (supplemental Table 6A, available at www.jneurosci.org as
supplemental material). The ACTH basal secretion after placebo
and prednisolone in the oCRH studies was not statistically differ-
ent from the corresponding morning and afternoon studies. For
cortisol, there was a trend toward reduced basal secretion after
prednisolone, and this did not reach significance (supplemental
Table 6A, available at www.jneurosci.org as supplemental
material).
Circulating POMC concentrations
POMC, the precursor of ACTH, was secreted into the circulation
with concentrations of 5–25 pmol/L (mean of 15 pmol/L) for the
morning studies, 17–100 pmol/L (mean of 63 pmol/L) for the
afternoon studies, and 17–130 pmol/L (mean of 43 pmol/L) for
the oCRH stimulation studies. Based on AUC assessment, the
POMC levels were significantly lower in the morning compared
with the afternoon ( p  0.001, two-tailed unpaired Student’s t
test). There was no inhibition of POMC secretion with pred-
nisolone during any timeframemeasured,
independent of time of day as assessed by
AUC (Fig. 7).
Interestingly, POMC was not stimu-
lated by oCRH over 180 min and even
after repeated CRH stimulation. Mean
POMCconcentrationswere 43 pmol/L af-
ter oCRH, which did not differ from pla-
cebo concentrations in the afternoon.
To assess whether POMC had any sig-
nificant pulsatility, the mean absolute
ApEn value was calculated. For POMC,
this was 1.03 0.07 with a ratio (to shuf-
fled) of 1.08 for the morning studies,
1.14  0.07 with a ratio (to shuffled) of
1.20 for the afternoon studies, and 1.12
0.06 with a ratio (to shuffled) of 0.91 for
the oCRH-stimulated studies. This indi-
cated that, in all of the studies over the
timeframe measured, the POMC concen-
tration series was 100% toward ran-
dom, indicating no significant pulsatility.
Experiment 4: GR andMR contribution
to prednisolone-mediated fast feedback
Pretreatment with spironolactone did
not modify the rapid inhibitory re-
sponse to prednisolone intervention,
nor were there any significant differ-
ences between the spironolactone and
placebo groups within any time domain using RM-ANOVA
(Fig. 8). Pretreatment with oral placebo was similar to previous
experiments (Figs. 1, 2, 8, 9). Furthermore, deconvolution anal-
ysis revealed a similar rapid pattern of inhibition of ACTH and
cortisol pulsatility with no statistically significant differences in
normalized average pulse mass according to timeframe between
the prednisolone intervention responses of the spironolactone
and placebo groups. Because of a lack of preintervention data, the
placebo intervention results could not be analyzed (supplemental
Tables 7B,C, 8B,C, available at www.jneurosci.org as supple-
mental material). There were no statistically significant differ-
ences seen in ACTH and cortisol basal secretion compared with
placebo preintervention with a reduction in ACTH basal secre-
tion ( p 0.005) only (supplemental Tables 7A, 8A, available at
www.jneurosci.org as supplemental material).
In contrast to the lackof effectwith spironolactone, pretreatment
with mifepristone did both reduce and delay the ACTH inhibition
after prednisolone ( p  0.05 normalized, RM-ANOVA). Specifi-
cally, in the mifepristone group (Fig. 9), acute administration of
prednisolone produced a significant decline in ACTH levels only
after 2 h ( p 0.05 absolute; p 0.001 normalized, RM-ANOVA)
and after 3 h for cortisol levels ( p  0.01 absolute; p  0.05
normalized, RM-ANOVA). A similar pattern could be seen for
normalized cortisol data but did not reach statistical significance.
There were no statistically significant differences between nor-
malized ACTH and cortisol (RM-ANOVA) in those pretreated
with mifepristone and placebo after placebo intervention.
Deconvolution analysis confirmed the loss of rapid inhibition
by prednisolone after mifepristone treatment (supplemental Ta-
bles 7B,C, 8B,C, available at www.jneurosci.org as supplemental
material). Prednisolone produced a significant reduction in av-
erage ACTH pulse mass only after 2 h compared with baseline
activity (ACTH, p  0.001 normalized), and no difference was
Figure6. Six healthymale subjects sampled at 10min intervals for ACTH (A) and cortisol (B) presented as groupmeans SEM.
Subjects attended twice and were given either an intravenous injection of 10 mg of prednisolone sodium succinate (black dia-
monds) or placebo (gray diamonds) over 5min at 4:32 P.M. (shaded line) and an injection of oCRH10min (gray dotted line) and3h
(gray dashed line) later at the dose of 1 g/kg. * denotes first significant difference between the prednisolone and placebo
interventionswith serial oCRHstimulation.Anexampleof a subject’s ACTHprofile after placeboandprednisolone is shown inC. The
corresponding mathematically modeled pulsatile activity is shown for placebo (D) and prednisolone (E) interventions, and puta-
tive pulse onsets denoted by black triangles above the time line.
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seen compared with placebo intervention over a similar time-
frame. There were no statistically significant differences seen in
cortisol average pulse mass (absolute and normalized). Indeed,
there was a trend to a larger ACTH and cortisol pulse mass in the
first 2 h after prednisolone intervention ( p 0.07 and p 0.08).
This reached statistical significance after 2 h for ACTH ( p 
0.05), and the trend continued for cortisol ( p  0.06). After
mifepristone and placebo intervention, there was no significant
change in average pulse mass (absolute and normalized) for
ACTH or cortisol throughout the sampling period.
Additionally, mifepristone pretreatment attenuated the re-
duction seen in basal ACTH secretion after prednisolone, with
mifepristone pretreatment resulting in statistically significant
larger basal ACTH secretion ( p 0.01) (supplemental Table 7A,
8A, available at www.jneurosci.org as supplemental material).
Discussion
Fast feedback was first described in the rat under conditions of
stress by Dallman and Yates in 1969 and later characterized as
part of a two-phase pattern of inhibition of HPA activity (Keller-
Wood and Dallman, 1984). Similar studies in man were per-
formed in hypoadrenal patients off replacement therapywho also
showed a similar two-phase period of feedback inhibition (Fehm
et al., 1979). The human inhibitory time course shows great vari-
ability and has been described as anything between 15 and 60min
(Reader et al., 1982; Posener et al., 1997; Boscaro et al., 1998).
Because of this variability, there has been uncertainty as to
whether the mechanisms underlying the feedback differed from
that in the animal model.
In our studies, we have used the HABS (Henley et al., 2009) to
enable us to do a full investigation of the patterns of HPA activity
under basal and feedback inhibition conditions. We used pred-
nisolone to induce feedback inhibition because it activates bothMR
Figure 7. POMC, the precursor of ACTH, was measured at the same time as ACTH in all
subjects, with placebo (gray diamonds) and prednisolone (black squares) given over 5 min
(shaded line).A showsmorning sampling,B shows afternoon sampling, and C shows afternoon
samplingwith exogenous oCRH stimulation 10min after intervention (dotted line) and 3h later
(dashed line). Results are presented as group means SEM.
Figure 8. 6 healthy male subjects sampled at 10 min intervals for ACTH and cortisol. Data
presented are group normalized ACTH means SEM (A). Subjects attended twice and were
given oral spironolactone at 9:30 A.M., followed by either an intravenous injection of 10 mg of
prednisolone sodium succinate (black diamonds) or placebo (gray diamonds) over 5 min at
12:02 P.M. (shaded vertical line). * denotes first significant difference between the pred-
nisolone and placebo interventions. B shows comparison of normalized mean SEM ACTH
responses after placebo (gray) and prednisolone (black) intervention with (diamonds) and
without (squares) spironolactone.
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and GR (Grossmann et al., 2004) and allowed us to measure HPA
responses without cross-reactivity with endogenous cortisol.
Resolving the ACTH and cortisol profiles into discrete pulses
of activity by deconvolution analysis revealed very rapid feedback
inhibition. Indeed, the pattern of inhibition was identical to the
rodent model (Atkinson et al., 2008) in which feedback inhibition
showed a distinct relationship with the phase of the endogenous
ultradian rhythm.We find that anypulse that has commenced at the
time of prednisolone injection was completed, whereas any sub-
sequent pulsatile activity was significantly smaller (30%). If,
however, prednisolone was given during the interpulse period,
subsequent pulsatile activity occurred at an appropriate time but
pulses were smaller than expected. Interestingly, the longer the
time after prednisolone to pulse onset, the greater the degree of
inhibition, with partial inhibition (50% of baseline activity) at 8
min and complete inhibition (30% of baseline activity) by
10–12 min. This rapid inhibition was present for ACTH and
cortisol and shows for the first time that, in the basal state, hu-
mans show rapid HPA negative feedback.
This relationship of feedback response with the phase of the
endogenous ultradian rhythm explains the marked variation in
previously documented speed and duration of feedback inhibi-
tion (Reader et al., 1982; Posener et al., 1997; Boscaro et al., 1998).
Because pulsatility is not synchronized between subjects and the
interpulse interval for ACTH is 40 min (Veldhuis et al., 1990)
and for cortisol is 80–110 min (Follenius et al., 1987; Veldhuis et
al., 1989), prednisolone-induced inhibition may occur from
minutes to 1 h for ACTH or up to 2 h for cortisol, emphasizing
the importance of adjuvant methods such as mathematical mod-
eling when examining “noisy” datasets.
It is also interesting to note that, as in the animal model
(Atkinson et al., 2008), some of our subjects demonstrated recov-
ery of endogenous cortisol pulsatility after approximately 5 h.
This only occurred in the afternoon, suggesting that, although
rapid inhibition itself was independent of time of day and conse-
quently CRH drive, response duration does depend on chrono-
biology. Because this recovery was seen for cortisol rather than
ACTH, it suggests involvement of a non-ACTH input such as the
splanchnic nerve (Ulrich-Lai et al., 2006) or intra-adrenal clock
(Son et al., 2008).
Deconvolution analysis also revealed that prednisolone re-
sulted in reduced basal secretion of ACTH. Because deconvolu-
tion analysis assumes a steady-state basal release, it is not possible
to ascertain whether inhibition of basal, as opposed to pulsatile,
secretion was similarly rapid or a genomically mediated gradual
decline. Interestingly, cortisol basal secretion was unaffected.
Serial injections of oCRH synchronized pulsatility allowed es-
timation of rapidity of feedback response to prednisolone in all
participants. Inhibition of the CRH response occurred within
20min for ACTHand typically30min for cortisol. Complete
inhibition of CRH stimulation occurred after the second injec-
tion of oCRH 3 h after prednisolone. These observations concur
with animal work (Zimmermann and Critchlow, 1969, 1972).
This is the first evidence for rapid feedback at the level of the
anterior pituitary gland in man and fits with early in vitro (Sayers
and Portanova, 1974) and in vivo (Jones et al., 1977) studies in the
rat. In the placebo wing of this study, the second oCRH injection
resulted in a blunted response as has been documented previ-
ously (Young et al., 2004), although basal ACTH secretion was
unaffected, suggesting an action of CRH on the pulsatile mecha-
nism only.
Although there is rodent data suggesting that fast feedback
can occur independent of protein synthesis (Keller-Wood and
Dallman, 1984) without modification of POMC processing to
ACTH (Roberts et al., 1982), there is no equivalent data in man.
We addressed this by the measurement of the release of unproc-
essed POMC for which we found no evidence of pulsatile release,
suggesting that it was not released through the normal regulatory
secretory pathway. POMC levels were higher in the afternoon
than in the morning, which may be a reflection of differential
processing of POMC into ACTH. Circulating POMC was unaf-
fected by either prednisolone or oCRH, further reinforcing the
concept that POMC is released from pituitary corticotrophs by
a constitutive pathway insensitive to corticosteroid feedback
(Pritchard andWhite, 2007). The fast inhibitory feedback of glu-
cocorticoids in man therefore appears to be selective for the reg-
ulated release mechanism.
Although pretreatment with the MR antagonist spironolac-
tone had no effect on the inhibitory response to prednisolone, the
selected GR antagonist mifepristone resulted in a significant re-
duction in the inhibition of ACTH and cortisol levels and pulse
mass.Mostmarkedwas the fact that, aftermifepristone, therewas
no significant feedback inhibition from prednisolone for 2 h, and
there was complete inhibition of the prednisolone-induced re-
duction of ACTH basal secretion.
The literature on the mechanism of rapid glucocorticoid in-
hibition of HPA activity is confusing. In the rat, there is in vivo
evidence that this involves anMR-mediated process (Atkinson et
al., 2008), whereas ex vivo, high levels of corticosterone (10- to
20-fold higher than binds classicalMR) inhibitory responses sug-
Figure 9. A, Group normalized ACTH means SEM for six healthy male subjects who at-
tended twice and were given oral placebo at 9:30 A.M., followed by either an intravenous
injection of 10mgof prednisolone sodiumsuccinate (black triangles) or placebo (gray triangles)
over 5minat 12:02P.M. (shadedvertical line). * denotes first significant differencebetween the
prednisolone and placebo interventions. B shows comparison of normalized mean  SEM
ACTH responses after placebo (gray) and prednisolone (black) with (triangles) and without
(squares) mifepristone.
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gest a less sensitive membrane-boundMR (Karst et al., 2005). At
the level of the pituitary in vitro, however, rapid inhibition of
membrane potential (Hua and Chen, 1989) and ACTH release
(Dayanithi andAntoni, 1989; John et al., 2002; Buckinghamet al.,
2003) occurs via a nongenomic Annexin 1-mediated GRmecha-
nism (Taylor et al., 1993). Our data reveal a response that is more
rapid than demonstrated for Annexin 1 and fits better with recent
in vitro and in vivo evidence for rapid corticosteroid processes
acting via a membrane-bound GR (Tait et al., 2008; Breuner and
Orchinik, 2009; Roy and Rai, 2009), probably mediated through
a phosphatidylinositol 3-kinase pathway (Limbourg et al., 2002;
Matthews et al., 2008; Roy and Rai, 2009). This suggests a fast
feedback inhibition that targets the fusion of ACTH-containing
vesicles with the cell membrane and their subsequent release
from corticotrophs and explains why the constitutive release of
POMC was unaffected.
It is of course possible that both GR and MR are involved in
negative feedback, with GR effecting a rapid nongenomic feedback
at the level of the anterior pituitary andMRsensinghigher glucocor-
ticoid levelswhile levels are still rising(Karst et al., 2005).Thesecould
exert different temporal dynamics and provide a feedback sensor
mechanismwith a wide range of sensitivity.
In conclusion, we provide novel evidence that HPA inhibitory
feedback responses to corticosteroids occur within a very rapid
time domain in man. This fast feedback inhibition is GR depen-
dent, independent of CRH drive, occurs predominately at the
level of the anterior pituitary, and only blocks the regulated path-
way of ACTH release. Our ability to detect these robust rapid
responses of HPA activity to exogenous corticosteroid feedback
in man will allow us to investigate mechanisms underlying ab-
normal HPA activity in conditions such as depression, obesity,
memory dysfunction, and aging.
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